OR13C5 and lung carcinoma: DNAH8, associated with prostate and lung cancers, also correlates with increased tumor mutation burden (TMB), suggesting its potential as a predictive biomarker for immune checkpoint inhibitor therapy [46,47] OR13C5, a member of the odorant receptors (ORs) family, may have implications beyond odor perception, potentially influencing glioblastoma pathogenesis and serving as biomarkers or therapeutic targets [48].